High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D
J Clin Oncol
.
2016 Dec 20;34(36):4307-4309.
doi: 10.1200/JCO.2016.70.2738.
Epub 2016 Nov 14.
Authors
Scott F Huntington
1
,
Amy J Davidoff
1
Affiliation
1
Scott F. Huntington, Yale School of Medicine and Yale Cancer Center, Yale University, New Haven, CT; and Amy J. Davidoff, Yale School of Public Health and Yale Cancer Center, Yale University, New Haven, CT.
PMID:
27998230
DOI:
10.1200/JCO.2016.70.2738
No abstract available
Publication types
Editorial
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Cost Sharing*
Drug Costs
Health Expenditures
Humans
Medicare
Medicare Part D*
United States